Stockscreener 앱 받기
0.2551
5.85%
0.0141
시간 외 거래:
.26
0.0049
+1.92%
전일 마감가:
$0.241
열려 있는:
$0.245
하루 거래량:
1.47M
Relative Volume:
0.13
시가총액:
$11.71M
수익:
-
순이익/손실:
$-23.74M
주가수익비율:
-0.0632
EPS:
-4.0366
순현금흐름:
$-16.70M
1주 성능:
-14.11%
1개월 성능:
+45.61%
6개월 성능:
-69.63%
1년 성능:
-81.43%
1일 변동 폭
$0.245
$0.2593
1주일 범위
$0.2213
$0.28
52주 변동 폭
$0.1628
$1.50
Theriva Biologics Inc Stock (TOVX) Company Profile
명칭
Theriva Biologics Inc
전화
301 417 4364
주소
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.2551 | 11.06M | 0 | -23.74M | -16.70M | -4.0366 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
CEO Moves: Is Theriva Biologics Inc subject to activist investor interest2026 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
TOVX Should I Buy - Intellectia AI
Theriva Biologics to reschedule stockholder meeting after lack of quorum By Investing.com - Investing.com Australia
Theriva Biologics, Inc. (TOVX) Files Form 8-K with SEC – Company Details and Exchange Information as of April 2026 - Minichart
Theriva Biologics to reschedule stockholder meeting after lack of quorum - Investing.com
Resistance Check: Is Theriva Biologics Inc in a long term uptrend2026 Rallies & Stock Market Timing Techniques - baoquankhu1.vn
Theriva Biologics Faces Delays in Warrant Approval Meeting - TipRanks
Theriva Bi Called Special Meeting Fails to Reach Quorum; Will Re‑call Meeting to Seek Approval for 16.18M Warrant Shares - TradingView — Track All Markets
Theriva Biologics (NYSE American: TOVX) resets vote on 16,184,560 warrant shares - Stock Titan
Aug Opening: Is Theriva Biologics Inc backed by strong institutional buyingEarnings Overview Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Aug Gainers: Why is Theriva Biologics Inc stock going downStock Surge & Consistent Growth Stock Picks - baoquankhu1.vn
Aug Shorts: Does Theriva Biologics Inc have pricing power2026 Fed Impact & Verified Short-Term Plans - baoquankhu1.vn
TOVX Technical Analysis & Stock Price Forecast - Intellectia AI
TOVX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Theriva Biologics (TOVX) Receives Upgrade from Maxim Group | TOV - GuruFocus
Theriva Biologics Raised to Buy From Hold by Maxim Group - Moomoo
Maxim Group Upgrades Theriva Biologics(TOVX.US) to Buy Rating, Raises Target Price to $1 - Moomoo
Analyst Calls: Is Theriva Biologics Inc showing insider buyingIPO Watch & Community Verified Swing Trade Signals - baoquankhu1.vn
Aug Intraday: Does Theriva Biologics Inc have pricing power2026 Institutional Moves & Daily Growth Stock Tips - baoquankhu1.vn
Portfolio Recap: Does Theriva Biologics Inc have strong EBITDA margins2026 Movers & Weekly Top Gainers Trade List - baoquankhu1.vn
Maxim Group Maintains Theriva Biologics(TOVX.US) With Hold Rating - Moomoo
Maxim Group Maintains Theriva Biologics(TOVX.US) With Hold Rating, Announces Target Price $0.22 - Moomoo
Theriva Biologics Receives FDA Agreement to Advance VCN-01 to Phase 3 Trial for Metastatic Pancreatic Cancer 1 - Minichart
Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA - TipRanks
Theriva Biologics Announces Positive End-Of-Phase 2 Meeting With U.S. FDA Regarding The Design Of A Phase 3 Trial Of VCN-01 In Metastatic Pancreatic Ductal Adenocarcinoma - MarketScreener
Theriva™ Biologics reports full-year 2025 operational highlights and financial results - MSN
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Stocktwits
Theriva Biologics (TOVX) Advances Phase 3 Clinical Trial Plans f - GuruFocus
Theriva Biologics Advances VCN-01 Into Pivotal Phase 3 - TipRanks
Theriva gets FDA alignment on phase 3 trial design for VCN-01 - Investing.com Canada
Theriva Biologics aligns with FDA on Phase 3 VCN-01 design for metastatic PDAC - TradingView
Theriva Biologics (NYSE: TOVX) gains FDA alignment on pivotal VCN-01 Phase 3 in metastatic PDAC - Stock Titan
Theriva™ Biologics Announces Positive End-of-Phase 2 - GlobeNewswire
Theriva pushes pancreatic cancer drug VCN-01 toward Phase 3 - Stock Titan
If You Invested $1,000 in THERIVA BIOLOGICS INC (TOVX) - Stock Titan
Theriva Biologics (TOVX) Registration Filing Summary - Quartr
Chart Watch: Is Theriva Biologics Inc showing insider buying2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
TOVX Stock Price, Quote & Chart | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
Aug Swings: Will Theriva Biologics Inc outperform its industry peers2026 Key Lessons & Risk Managed Investment Signals - baoquankhu1.vn
Theriva Biologics (NYSE: TOVX) puts 16.2M warrant share issuance to vote - Stock Titan
Theriva Biologics, Inc. (TOVX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Bitget
TOVX Reports Strong Cash Position and Funding Plans for Clinical Trials - GuruFocus
Theriva 10-K: Net loss $23.74M, EPS $(2.08); Operating loss $24.05M - TradingView
Theriva Biologics reports $13.1M year-end cash, $25.2M net loss for 2025 - TradingView
Form 10-K Theriva Biologics, Inc. For: Dec 31 - StreetInsider
Theriva Biologics (NYSE: TOVX) details 2025 loss and cash runway into 2027 - Stock Titan
Cancer drug developer Theriva inks SYN-020 deal up to $38M - Stock Titan
Theriva Biologics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Mood: Can Theriva Biologics Inc maintain sales growthStock Surge & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Theriva Biologics Inc (TOVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):